WilmerHale Represents Medtronic in $337 Million Product Investment from Blackstone Life Sciences to Expand Development of Diabetes Technologies

WilmerHale Represents Medtronic in $337 Million Product Investment from Blackstone Life Sciences to Expand Development of Diabetes Technologies

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Offering a sophisticated, full-service solution to private equity sponsors and entrepreneurs, from initial investment to exit.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
Critical industry insight and formidable strength across key practices.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
On June 12, 2020, Medtronic plc (NYSE: MDT) and Blackstone (NYSE: BX) announced that they have entered into a definitive agreement under which Medtronic would receive up to $337 million of funding from funds managed by Blackstone Life Sciences, including co-investors, aimed at advancing new, innovative products especially designed to reduce the burden of diabetes management. The investment from Blackstone Life Sciences, its first such collaboration in the medical devices space, is expected to accelerate Medtronic’s diabetes pump and continuous glucose monitor technology pipeline. Under the terms of the agreement, Medtronic will receive up to $337 million in funding over the next several years to fund four identified Diabetes R&D programs, and Medtronic’s engineering, clinical, and regulatory teams will perform the development work to activate these programs. If successfully commercialized, Medtronic will pay royalties which are expected to be in the low- to mid-single digit range as a percentage of sales.

WilmerHale is representing Medtronic in the transaction, with a team led by Partners Chris Barnstable-Brown and Steve Barrett, which included Associate Elizabeth Mayo on corporate matters and Partner Julie Hogan Rodgers on tax matters.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel